Home | News | Find a Doctor | Ask a Question | Free

Intercytex what a P*** take - Interim results


#1

ICX-TRC - hair regeneration

Data from the Phase II trial shows increase in hair count in 11 out of 14 (79%) evaluable subjects at 24 weeks

ICX-TRC - Hair regeneration
ICX-TRC consists of a suspension of autologous dermal papilla (DP) cells. These cells are able to
stimulate the generation of new hairs when injected into the scalp in close proximity to the epithelial
cells which generate the hair. The purpose of the ongoing Phase II study being conducted by Dr
Bessam Farjo in Manchester is to optimise the delivery of the DP cells.
In this study, hair counts are obtained by shaving and photographing a small section of scalp,
injecting it and then applying a specialised image analysis system to provide a total hair count. Two
sub-groups were each injected with autologous DP cells using different delivery techniques. The first
group focussed on delivery of the hair inductive DP cells, and in the second group resident hair
producing (epithelial) cells were also stimulated at the time of delivery.
At 24 weeks the results are as follows:
• Of the five subjects who received DP cells with no pre-stimulation of the scalp three (60%)
showed an increase in hair counts
• Of the nine subjects who received DP cells with pre-stimulation of the scalp eight (89%)
showed an increase in hair counts
• Two subjects were not evaluable at this time-point
At the end of Q1 next year when the trial has concluded, photographic data will be analysed from a
much larger area of treated scalp on all subjects at 12 months. Currently three subjects have been
lost to follow up.
We are continuing to explore partnering opportunities to continue the next clinical phase of
development of ICX-TRC. Bosley, the largest chain of hair transplant clinics in the US, has an option
to negotiate distribution rights to this product.

That was really worth the wait - No bloody pictures - our Baccy is doing better.Great job Baccy!


#2

» ICX-TRC - hair regeneration
»
» Data from the Phase II trial shows increase in hair count in 11 out of 14
» (79%) evaluable subjects at 24 weeks
»
» ICX-TRC - Hair regeneration
» ICX-TRC consists of a suspension of autologous dermal papilla (DP) cells.
» These cells are able to
» stimulate the generation of new hairs when injected into the scalp in
» close proximity to the epithelial
» cells which generate the hair. The purpose of the ongoing Phase II study
» being conducted by Dr
» Bessam Farjo in Manchester is to optimise the delivery of the DP cells.
» In this study, hair counts are obtained by shaving and photographing a
» small section of scalp,
» injecting it and then applying a specialised image analysis system to
» provide a total hair count. Two
» sub-groups were each injected with autologous DP cells using different
» delivery techniques. The first
» group focussed on delivery of the hair inductive DP cells, and in the
» second group resident hair
» producing (epithelial) cells were also stimulated at the time of
» delivery.
» At 24 weeks the results are as follows:
» • Of the five subjects who received DP cells with no pre-stimulation of
» the scalp three (60%)
» showed an increase in hair counts
» • Of the nine subjects who received DP cells with pre-stimulation of the
» scalp eight (89%)
» showed an increase in hair counts
» • Two subjects were not evaluable at this time-point
» At the end of Q1 next year when the trial has concluded, photographic data
» will be analysed from a
» much larger area of treated scalp on all subjects at 12 months. Currently
» three subjects have been
» lost to follow up.
» We are continuing to explore partnering opportunities to continue the next
» clinical phase of
» development of ICX-TRC. Bosley, the largest chain of hair transplant
» clinics in the US, has an option
» to negotiate distribution rights to this product.
»
»
» That was really worth the wait - No bloody pictures - our Baccy is doing
» better.Great job Baccy!

This means… a big nothing!! This could be the report of the last year, the info are the same, no new news or discovers… The same percentage %% without ANY REFERENCES… so 79% of what?? How many hairs means that… 7 hairs?? 70 hairs?? I think that 7 will be a good number for them, so in the next Q3 of the 2017 the will have more data to analize and release the PHASE 2(3) results…
Yes, i think baccy is doing a better work :stuck_out_tongue:


#3

They seem to keep losing trialists to follow-up. At one point they were advertising for trialists in local newspapers DESPITE having both Baldie42 and myself on their books ready for prescreening.
The irony is that if they would have called me in for trials, I would have stuck with it. I wouldn’t have been lost to follow-up.


#4

Whats the problem? they never promised pictures until the endof phase II.

Losing 3 patients to follow up is not that big a deal. For example they could have died, left the country or simply unavailable on the evaluation day.

Of course they could have left the program because results weren’t as expected etc.

People act as if ICX owe them something, which is ridiculous.
If they don’t provide pics and more detailed results by the end of phase II, then theres reason to be pissed off.


#5

» People act as it ICX owe them something, which is ridiculous.

yes, and now they think that follica will say and do the things that they want to be said and done


#6

Look at one of the last page of the document, they have a slide that are talking about 2 ways to use ICX-TRC…

  • In vitro ( proto hair )
  • In vivo

It looks like they are trying or will try protohair…

What’s your thought???


#7

» Look at one of the last page of the document, they have a slide that are
» talking about 2 ways to use ICX-TRC…
»
» - In vitro ( proto hair )
» - In vivo
»
» It looks like they are trying or will try protohair…
»
» What’s your thought???

Can you post it please? I can’t see it anywhere.


#8

» We are continuing to explore partnering opportunities to continue the next
» clinical phase of
» development of ICX-TRC. Bosley, the largest chain of hair transplant
» clinics in the US, has an option
» to negotiate distribution rights to this product.

It almost seems like ICX has toned down the partnership talks. Last time, they were talking about how it was necessary to partner w/ someone else or else there would be no phase III; here that tone of necessity isn’t there. Either they just didn’t feel like repeating themselves, or they don’t feel they HAVE to partner w/ another group to do phase III.


#9

an “increase in hair counts” could mean 1-2 additional hairs.

not impressed.


#10

they have a 90% success rate

they also say 900 injections which is one would think leads to a lot of new hair growth

here is the file

http://www.intercytex.com/icx/investors/rep/rep2008/2008-09-18/2008-08-19.pdf


#11

» » We are continuing to explore partnering opportunities to continue the
» next
» » clinical phase of
» » development of ICX-TRC. Bosley, the largest chain of hair transplant
» » clinics in the US, has an option
» » to negotiate distribution rights to this product.
»
»
» It almost seems like ICX has toned down the partnership talks. Last time,
» they were talking about how it was necessary to partner w/ someone else or
» else there would be no phase III; here that tone of necessity isn’t there.
» Either they just didn’t feel like repeating themselves, or they don’t feel
» they HAVE to partner w/ another group to do phase III.

Wow, talk about reading too much into things.

Bosley has first dibs, if they don’t want it after a certain amount of time they are open to offers, so to speak.


#12

No info here.


#13

Nathans link:

Anyone read the last page “KEY PRIORITIES”?

Very disappointing that there is no mention of ICX-TRC :frowning: . It doesn’t look like there is much motivation when it comes to their ICX-TRC product. That can’t possibly be a good sign. I hope that I am wrong


#14

Good point.

ICX is probably not going to help us in the foreseeable future. It’s becoming clearer all the time.


#15

» This means… a big nothing!! This could be the report of the last year,
» the info are the same, no new news or discovers… The same percentage %%
» without ANY REFERENCES… so 79% of what?? How many hairs means that… 7
» hairs?? 70 hairs?? I think that 7 will be a good number for them, so in the
» next Q3 of the 2017 the will have more data to analize and release the
» PHASE 2(3) results…
» Yes, i think baccy is doing a better work :stuck_out_tongue:

QUOTE ALL!


#16

I’m right?


#17

» I’m right?
Is intercytex’s TRC product dead?
Not Sure.

.


#18

I/We wait a half year of a new update and than this sh****t!


#19

» I/We wait a half year of a new update and than this sh****t!
Exactly. I said this before, and I’ll say it again. I think their technology has some merit, BUT I think their management team is incompetent.

.


#20

» » I/We wait a half year of a new update and than this sh****t!
» Exactly. I said this before, and I’ll say it again. I think their
» technology has some merit, BUT I think their management team is
» incompetent.
»
»
» .
What can we do…,look at follica or Baccy:-)